. The participation of DBI and of its processing product DBI-(33-50) (octadecaneuropeptide, ODN) in the regulation of insulin secretion (6, 15) , the role of DBI-(17-50) (triakontatetraneuropeptide, TTN) (16, 17) and des(Gly-I1e)-endozepine or des(Gly-Ile)-DBI in the regulation of steroidogenesis (18) were screened for DBI-specific sequences with a32P-labeled probe generated by PCR using rat DBI cDNA (2) as template and 5'-CGCTCTAGAGCCAGTATGTCTCAG-GCTGA-3' and 5'-GCGAAGCTTAGGCATTATGTCCTCA-CAGG-3' as oligodeoxynucleotide primers. Positive clones were further characterized by Southern hybridization. Appropriate restriction fiagments were subcloned into pBluescript KS(-) (Stratagene). For determination of the nucleotide sequence, exonuclease III deletion libraries were generated by a nested-deletion kit (Pharmacia). The nucleotide sequence of Abbreviations: DBI, diazepam binding inhibitor; ACBP, acyl-CoAbinding protein; GRE, glucocorticoid-responsive element.
' untrasted rgion of the DBI gene showed that basal promoter actiity requhled 146 bp of the proximal DBI sequence, whereas full activation was achieved with 423 bp of the 5' untransated region. DNase I protection experiments with liver nuclear proteins demonstrated three protected regiom at nt -387 to -333, -295 to -271, and -176 to -139 rdative to the ATG itiation codon; in other tissues the pattern of protection was dierent. In gel shift assays the most proximal region (-176 to -139) was found to bind several general trnsciption factors as well as cell typresicted nuclear proteins which may be related to specific regulatory patterns in diferent tissues. Thus, the DBI gene some features of a housekeeping gene but also incudes a variable regulation which appears to change with the function that it subserves in dferent cell types.
Diazepam binding inhibitor (DBI) is a 10-kDa polypeptide that was first purified and partially sequenced from rat brain (1) by monitoring its ability to displace diazepam from brain synaptic membrane recognition sites where this anxiolytic ligand binds with high affinity to type A -t-aminobutyrate receptors and mitochondrial benzodiazepine receptors. The complete amino acid sequence of DBI was deduced from clones derived from rat (2) and human (3) brain cDNA libraries. The amino acid sequences for DBI have been obtained for rat (1, 4) , human (3) , duck (5), pig (6) , and cow (5) . cDNAs have been cloned for human (3, 7) , rat (2) , mouse (8) , and cow (7, 9) . The DBI cloned from human brain has a longer amino acid sequence (103 aa) than that reported for other species, suggesting that in humans a difference in DBI structure may arise from alternative splicing (3) .
More recently DBI has been purified from several peripheral organs (reviewed in ref. 10) , and DBI-like immunoreactivity and DBI mRNA were detected in several tissues (11, 12) . In rat brain DBI is located in selected neuronal and glial cell populations (such as Bergmann glia) (13) . In adrenal
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gland DBI is expressed in cortical cells, whereas the chromaffin cells are immunonegative (14) . The participation of DBI and of its processing product DBI-(33-50) (octadecaneuropeptide, ODN) in the regulation of insulin secretion (6, 15) , the role of DBI-(17-50) (triakontatetraneuropeptide, TTN) (16, 17) and des(Gly-I1e)-endozepine or des(Gly-Ile)-DBI in the regulation of steroidogenesis (18) , of acyl-CoA ester metabolism (4) and the action of DBI as a negative allosteric modulator of the function of type A -t-aminobutyrate receptors have been established (10) .
Chromosomal localization experiments using in situ hybridization techniques in human cells (19) , as well as Southern blot hybridization of rat (2) (20) , and the rat genomic sequence of the DBI/ACBP gene and four processed pseudogenes has been reported (21 the rat DBI gene was determined by the chain-termination method (22) . Sequencing reactions were carried out with an AutoRead sequencing kit (Pharmacia), and the reaction products were analyzed with an A.L.F. automated DNA sequencer (Pharmacia). DNA sequence data were analyzed by the Genetics Computer Group software package (23) . Molecular cloning procedures were carried out essentially as described (24) . Radioactive compounds were from Amersham.
RNA Isolation and RNase Protection Assay. RNAs from rat tissues were prepared as described (25) . For determination of the mRNA start sites, a genomic fragment covering 145 bp of 5' untranslated region, exon 1, and 110 bp of intron 1 (nt -146 to +119 in Fig. 1 ) was cloned into pBluescript KS(-). cRNA probes were synthesized using T7 and SP6 RNA polymerases (Promega) and [a-32P]CTP on linearized plasmid templates. RNase protection assays were carried out with the RPA II kit (Ambion). RNA quality was assessed by RNase protection assay using rat cyclophillin cDNA (nt 411-705) cloned into pGEM-1 as a probe (26) .
DBI Promoter-Luciferase Constructs, Celi Culture, and Transfection. All DBI promoter fragments were cut by Kpn I/Nhe I digestion from various clones of the exonuclease III deletion library (the Kpn I site is from the pBluescript KS(-) vector and the Nhe I site is located at position -84 in Fig. 1 ) and cloned into Kpn I/Nhe I-digested pGL-Basic luciferase reporter plasmid (Promega). The DBI promoter-luciferase constructs were pGLbDB122 (containing nt -1061 to -84) pGLbDBI31 (nt -423 to -84), and pGLbDBI41 (nt -146 to -84).
C6 rat glioma cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, gentamicin, and 2 mM glutamine. The DNAs used for transfections were purified with the Magic maxipreps system (Promega). DNA transfections were performed with a calcium phosphate mammalian cell transfection kit (5 Prime-3 Prime, Inc.) according to the manufacturer's instructions. Promoter-luciferase construct (10 ,g ) and the reference plasmid pON260 (2 ,ug), expressing ,-galactosidase (27) , were used to transfect C6 cells on 90-mm tissue culture dishes. Sixty hours after transfection, cells were harvested with 10 mM EDTA in phosphate-buffered saline (140 mM NaCl/3 mM KCl/5.4 mM Na2HPO4/2 mM KH2PO4, pH 7.4) and washed once with phosphate-buffered saline. Half of the cells were used for protein assay (28) and j-galactosidase assay (24) . The other half was used for the luciferase assay, which was performed with a kit (Promega) according to the manufacturer's instructions. Luciferase activities were expressed as relative units compared to simian virus 40 early promoter-directed luciferase activity pGL-Control plasmid (Promega)], after normalization to the protein content and /-galactosidase activity.
DNase I Footprints. A restriction fragment (200 ng; nt -423 to -84 in Fig. 1 ) was end-labeled with T4 polynucleotide kinase (Promega) and [r-32P]ATP and used as a probe in a DNase I protection assay as suggested by the kit manufacturer (GIBCO/BRL), with the following modification. Total nuclear protein extract (5 ug) or 1 footprint unit of recombinant Spl protein (Promega) was mixed with 20,000 cpm of the probe and incubated for 30 min at room temperature. DNase 1 (5 ng) was then added, and 1 min later the reaction was stopped and the reaction products were analyzed by electrophoresis in a denaturing polyacrylamide gel. The same fragment was subjected to a sequencing reaction by the chemical modification method (29) to localize the precise region(s) involved in protein binding.
Nuclear Protein Extract and Electrophoretic Mobility Shift.
Nuclear proteins were extracted from various rat tissues (30) and pancreatic islets (31) . The buffer and running conditions for the mobility-shift assay were as reported (32) . (Fig. 2) levels are relatively high (4) . Footprint experiments with liver nuclear protein extracts revealed two protected regions, nt -333 to -387 (Fig. 4A) and -295 to -271; whereas the first was also protected by nuclear extract ofpancreatic islets and partially by nuclear extracts of adrenal and brain, the region at -295 to -271 was liver-specific (Fig. 4B) , suggesting that a tissue-restricted factor might bind to it. Recombinant Spl also protected the region between -350 and -325 in the DBI promoter (Fig. 4A) , partly overlapping the region protected by liver nuclear protein extract. A sequence similar to the consensus binding site for transcription factor Spl was located at nt -339 and -333 (upper strand, CACGCCC); however, the fact that Spl can protect some DNA sequences not protected by the liver nuclear extract argues that in liver, Spl could be bound to this particular region. A region further downstream, at -177 to -147, was also protected by recombinant Spl protein (data not shown). The latter corresponded to an area containing consensus sites for Spl and CAATbinding factors as revealed by a computer-assisted analysis (Fig. 1) . To investigate whether or not the promoter for the rat DBI gene could recruit divergent protein complexes in different tissues, a region between nt -136 and -176 was challenged with nuclear proteins extracted from adrenals, brain, pancreatic islets of Langerhans, and liver. In each of the above tissues a dissimilar yet very specific function has been extensively described (10) . Mobility-shift assay showed that every extract included complexes with a different migration profile. Although the total amounts of protein were comparable and control experiments showed no signs of protein degradation (data not shown), the relative abundance ofthe shifted bands differed dramatically (e.g., islets and liver in Fig. 5A ). The gel shift experiments revealed three possible regulatory protein complexes (Bi, B2, and B3 in Fig. 5A (38) . Another level of such cell-restricted regulation is shown by the AP1 consensus (39), which was able to compete with the same Spl-bound complexes only in liver nuclear extract (Fig. SA) . Finally, in brain nuclear extract, only the oligonucleotide with the same sequence as the probe competed with the probe for formation of the complex B3, indicating that in some tissues DBI gene could also be regulated by other specific nuclear factors. These findings allow us to infer that two orders of control regulate the DBI gene, one probably common to all tissues and related to its housekeeping structure and another, which presumably expresses a transcriptional control related to each ofthe multiple biological actions of DBI and therefore might be regulated by cell-specific signals.
Since the transient expression experiments showed that the DBI promoter activity was greatly reduced when sequence upstream from nt -146 was removed (Fig. 3) , and since a cluster of putative AP2 sites was present between -321 and -295, an oligonucleotide spanning that region was synthesized. Once again the pattern of bound complexes differed significantly among the tissues tested, confirming the tissue-restricted regulation of the DBI promoter (Fig. SB) .
Condcusions. We have cloned and characterized part of the rat DBI gene covering 4 kb of the 5' untranslated region, the first two exons, intron 1, and part of intron 2. The putative promoter region of the DBI gene was functionally characterized by transient expression studies in the C6 rat glioma cell line. It was shown that the 423-bp sequence upstream from the translation initiator codon was responsible for the complete activity of the DBI promoter in C6 cells. Mapping of the 5' ends of DBI mRNA revealed multiple transcriptional startpoints in all tissues studied. Remarkable differences were found in the transcriptional startpoint usage among different tissues. DNase I protection assay using a nuclear protein extract from rat liver with the -423 promoter fagment of the DBI gene revealed several protected regions. Two of these regions were also protected with recombinant Spl protein. Different efficiencies in mRNA cap-site usage by different tissues, as well as detection oftissue-specific DNAprotein complexes (footprints and gel shift assay with several other tissues and cell lines), substantiate the tissue segregation of different protein complexes. These findings strongly suggest the possibility of complicated regulatory patterns of DBI gene expression in different cell types according to the specific functional tasks. Further, the existence of DBI mRNAs with different 5' untranslated regions suggests that the DBI gene might be also regulated at the translational level. Accordingly, preliminary evidence of alternative splicing observed in the rat DBI mRNA 5' untranslated region (M.K. and H.A., unpublished data) supports the view that the DBI gene, thought to be a housekeeping gene (21) , is subject to additional regulatory mechanisms probably related to functional tissue specificities subserving the multiple biological activities of this peptide present in different tissues (4, 10) .
